Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 80.55% shareholder participation, with 112,499,671 of 139,663,680 shares represented.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 80.55% shareholder participation, with 112,499,671 of 139,663,680 shares represented
- Anand Mehra and Maxine Gowen elected directors through 2029
- Executive compensation approved advisory, with 83,370,124 votes for and 9,734,691 against
- PwC ratified as independent auditor for fiscal 2026, with 112,322,811 votes for
- Director elections included 19,360,478 broker non-votes, limiting voting participation on those nominees
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.